Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Lee, Jae-Seon [1 ]
Park, Min Ji [1 ]
Sun, Ningning [1 ]
Park, Jin-Hee [1 ]
Oh, Su-jin [1 ]
Moon, Miran [1 ]
Kim, Myung Jin [1 ]
Jang, Soo Yeon [1 ]
Kim, Yong-Chul [1 ]
机构：
[1] PeLeMed, Seoul, South Korea
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [2] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [3] Evaluation of a FLT3 inhibitor as an anti-leukemic agent for acute myeloid leukemia
    Jeong, Pyeonghwa
    Lee, Jungeun
    Lee, Hyo Jeong
    Baek, Juhwa
    Choi, Jungil
    Chin, Young-Won
    Choi, Young Hee
    Kim, Yong-Chul
    Han, Sun-Young
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [4] Discovery of PLM-102, a highly potent 3rd generation FLT3 inhibitor, in drug-resistant FLT3-ITD-TKD mutated acute myeloid leukemia
    Park, Jin-Hee
    Lee, Jae-Seon
    Oh, Su-Jin
    Lee, So-Deok
    Choi, Yong June
    Kang, Keon Wook
    Moon, Miran
    Jang, Soo Yeon
    Kim, Myung Jin
    Kim, Yong-Chul
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Zhang, Yvyin
    Wang, Peihong
    Wang, Yang
    Shen, Yang
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [6] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Yvyin Zhang
    Peihong Wang
    Yang Wang
    Yang Shen
    Biomarker Research, 11
  • [7] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
    Numan, Yazan
    Abdel Rahman, Zaid
    Grenet, Justin
    Boisclair, Stephanie
    Bewersdorf, Jan Philipp
    Collins, Cailin
    Barth, Dylan
    Fraga, Martina
    Bixby, Dale L.
    Zeidan, Amer M.
    Yilmaz, Musa
    Desai, Pankil
    Mannis, Gabriel
    Deutsch, Yehuda E.
    Abaza, Yasmin
    Dinner, Shira
    Frankfurt, Olga
    Litzow, Mark
    Al-Kali, Aref
    Foran, James M.
    Sproat, Lisa Z.
    Jovanovic, Borko
    Daver, Naval
    Perl, Alexander E.
    Altman, Jessica K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
  • [8] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [9] Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia
    Lee, Hyo Jeong
    Lee, Jungeun
    Jeong, Pyeonghwa
    Choi, Jungil
    Baek, Juhwa
    Ahn, Su Jin
    Moon, Yeongyu
    Heo, Jeong Doo
    Choi, Young Hee
    Chin, Young-Won
    Kim, Yong-Chul
    Han, Sun-Young
    ONCOTARGET, 2018, 9 (01) : 924 - 936
  • [10] Development of PLM-102, a novel dual inhibitor of FLT3 and RET as a new therapeutic option for acute myeloid leukemia.
    Kim, Myungjin
    Oh, Su-jin
    Kim, WooChan
    Choi, Yong June
    Lee, Jae-Seon
    Lee, So-Deok
    Park, Jin-Hee
    Lee, Eun Ji
    Kang, Keon Wook
    Jang, Soo Yeon
    Kim, Yong-Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345